Cugene recently delivered an oral presentation on CUG252, a long-acting Treg-selective IL-2 with high specificity and low toxicity, aimed at restoring immune homeostasis and self-tolerance for treating autoimmune and inflammatory diseases. CUG252 shows a promising best-in-class profile among IL-2 variants, offering superior Treg selectivity while maintaining potency comparable to wild-type IL-2.